<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic nonallergic rhinitis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic nonallergic rhinitis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic nonallergic rhinitis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Phillip L Lieberman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Corren, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 22, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic nonallergic rhinitis (NAR) is not a specific disease but rather a syndrome diagnosed by excluding other specific types of rhinitis. The pathogenesis, incidence, clinical manifestations, diagnosis, and treatment of chronic NAR are presented in this topic review. Allergic rhinitis and an overview of other forms of rhinitis are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">
          "Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">
          "Pharmacotherapy of allergic rhinitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">
          "Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">
          "An overview of rhinitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         NAR is best defined by the chronic presence of one or more of the four following cardinal symptoms of rhinitis, in the absence of a specific etiology (such as an immunologic, infectious, pharmacologic, structural, hormonal, vasculitic, metabolic, or atrophic cause):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sneezing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhinorrhea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal congestion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postnasal drainage
        </p>
        <p>
        </p>
        <p>
         Although there is no consensus about how long symptoms should be present to establish chronicity, some studies have utilized a minimum duration of over one year [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The lack of clarity regarding the pathogenesis of this condition has led to an imprecise terminology and a number of synonyms used to refer to this entity. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Idiopathic rhinitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonallergic, noninfectious rhinitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intrinsic rhinitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasomotor rhinitis or nonallergic vasomotor rhinitis
        </p>
        <p>
        </p>
        <p>
         Some experts use the term "nonallergic rhinitis" to refer more generally to any form of rhinitis that is noninfectious and nonallergic [
         <a href="#rid3">
          3
         </a>
         ]. However, in this topic review, NAR is used more narrowly, as defined above.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          THEORIES OF PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no single unifying theory of pathogenesis for chronic NAR, and it may represent a group of incompletely defined disorders [
         <a href="#rid4">
          4-6
         </a>
         ]. However, NAR can be broadly divided into noninflammatory and inflammatory forms [
         <a href="#rid7">
          7-34
         </a>
         ], with the inflammatory form being further divided into cases that are either eosinophilic or noneosinophilic processes [
         <a href="#rid1">
          1,2,7-34
         </a>
         ]. With all forms of chronic NAR, there is also a variable component of autonomic dysregulation. In the noninflammatory form, these neurologic abnormalities are the only demonstrable findings.
        </p>
        <p>
         Patients with NAR often exhibit a clinical hypersensitivity to odors, which is usually manifested by the production of rhinitis symptoms. One group of researchers evaluated the neurogenic responses to chemical/olfactory stimuli in patients with NAR using functional magnetic resonance imaging (MRI) [
         <a href="#rid35">
          35
         </a>
         ]. Subjects underwent MRI during exposure to different types of odors. They exhibited increased blood flow to several odor-sensitive regions of the brain in response to both pleasant (vanilla) and unpleasant (hickory smoke) odors. The neurologic responses were associated with the production of symptoms upon exposure to hickory smoke. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Noninflammatory
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the noninflammatory form (as defined by biopsies negative for inflammation), it has been postulated that the disease results from an abnormality in the autonomic nervous system, including the adrenergic, cholinergic, and/or nonadrenergic-noncholinergic (NANC) innervation of the nose [
         <a href="#rid9">
          9-12
         </a>
         ]. However, such abnormalities have also been demonstrated in some inflammatory cases and, in this context, have been proposed to be secondary to a primary inflammatory process [
         <a href="#rid7">
          7,8,12,29
         </a>
         ]. Thus, the pathogenic role of these abnormalities is unclear.
        </p>
        <p>
         "Gustatory rhinitis" is a term applied to the development of profuse, watery rhinorrhea or congestion in association with eating hot or spicy foods [
         <a href="#rid36">
          36
         </a>
         ] (see
         <a class="local">
          'Prominent rhinorrhea without other symptoms'
         </a>
         below). It is most likely a subtype of noninflammatory NAR.
        </p>
        <p>
         Patients with noninflammatory NAR may display the following abnormal neurologic findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal responses to various neurogenic stimulation, including heightened responses (in the form of rhinitis symptoms) to histamine, cold stimulation of the extremities and nasal mucosa,
         <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">
          methacholine
         </a>
         , and other stimuli designed to activate cholinergic responses [
         <a href="#rid7">
          7,10,29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diminished responses to vasoconstrictive stimuli [
         <a href="#rid37">
          37
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased concentrations of intranasal neuropeptides, such as vasoactive intestinal peptide (VIP) and substance P [
         <a href="#rid16">
          16
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In addition to these neural processes, nasal secretory abnormalities may also be important to the pathogenesis of NAR. In one study, subjects with allergic rhinitis secreted higher amounts of albumin and an unidentified 26 kilodalton protein than did those with NAR [
         <a href="#rid38">
          38
         </a>
         ]. Since production of the latter protein could be stimulated by
         <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">
          pilocarpine
         </a>
         , it was thought to occur in secretory mucosal glands. This implies that there is a qualitative difference in the glandular mucosa, which may distinguish patients with allergic rhinitis from those with NAR.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Inflammatory
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonallergic rhinitis with nasal eosinophilia syndrome (NARES) is the most common type of inflammatory NAR. The clear nasal secretions in these patients contain greater than 25 percent eosinophils. Nasal biopsies from these patients commonly show increased eosinophils, as well as increased numbers of mast cells and prominent mast cell degranulation [
         <a href="#rid2">
          2,19
         </a>
         ]. The presence of eosinophils in nasal secretions can be assessed in the office by having the patient blow the nose into a piece of "wax paper" and applying the secretions onto a glass slide. Once dried, the secretions are stained with Wright's stain and examined under a light microscope. Although not considered essential for the diagnosis, the author has performed this examination for years and has found that the presence of abundant eosinophils usually predicts a good response to intranasal corticosteroids (INCS).
        </p>
        <p>
         The cellular inflammatory infiltrate may have dominant cells other than eosinophils. Nasal cytology, in some cases, shows a predominance of mast cells and neutrophils [
         <a href="#rid39">
          39,40
         </a>
         ]. There may also be an increase in mucus-producing cells [
         <a href="#rid41">
          41
         </a>
         ]. These histologic findings may be associated with different clinical manifestations [
         <a href="#rid39">
          39
         </a>
         ]. In one study, the burden of inflammatory cells correlated with impaired quality of life [
         <a href="#rid41">
          41
         </a>
         ]. As noted above, the presence of eosinophilia can indicate responsiveness to corticosteroids. It may also be associated with a higher incidence of asthma and more severe symptoms than when the predominant pattern is characterized by neutrophilia. When mast cells are the predominant cell type, nasal itching is often a characteristic feature [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The inflammatory cytokine pattern in chronic NAR differs from normals. A study comparing patients with allergic rhinitis, NAR, and controls found that both patient groups had increased levels of interleukin 16 and interleukin 17 compared with controls [
         <a href="#rid42">
          42
         </a>
         ]. Significantly higher serum levels of the costimulatory molecule sCD48 occurred in the nonallergic group, and significant correlations were noted between the serum level of sCD48 and the number and percentage of eosinophils and eosinophilic cationic protein. Eotaxin-1/CCL11 serum levels were also found to be significantly higher in the nonallergic group [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Patients with allergic rhinitis and NAR had significantly different microbiota profiles compared with healthy controls [
         <a href="#rid44">
          44
         </a>
         ]. The results suggest that the nasal microbiota may play a key role in the pathogenesis and symptoms of allergic and nonallergic phenotypes, providing us with new ideas for the therapy of these disorders.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Evidence for a localized allergic response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic NAR have negative skin and in vitro tests for allergen-specific immunoglobulin E (IgE) by definition and thus lack evidence of increased systemic production of allergen-specific IgE. However, IgE production may occur locally in the nasal tissue in patients with negative skin tests, as well as in patients with typical allergic rhinitis [
         <a href="#rid2">
          2,45-52
         </a>
         ]. One group of investigators has shown that up to one-half of patients with chronic NAR react to nasal challenge with allergen, especially dust mite allergen, with symptoms and signs similar to those in patients with typical allergic rhinitis and significantly different from controls without rhinitis [
         <a href="#rid46">
          46,53,54
         </a>
         ]. Local IgE production in the nasal mucosa has been demonstrated to additional allergens, including pollens, animal epithelia, molds (
         <em>
          Alternaria
         </em>
         ), and others. Basophils from peripheral blood may be activated by the involved allergens, suggesting spillover of locally synthesized specific IgE into the circulation. Because of these findings, some authors have suggested performing an allergen-specific nasal challenge and/or measuring the (local) nasal-specific IgE levels in addition to standard allergy tests in this subgroup of patients. In addition, they recommend repeating allergy skin testing "after a time interval" since patients formerly diagnosed with NAR may develop allergic disease [
         <a href="#rid55">
          55-57
         </a>
         ].
        </p>
        <p>
         It is possible that the production of local allergen-specific IgE in patients with symptoms of rhinitis is simply a precursor to the development of the systemic production of these IgE antibodies. A prospective 10-year follow-up study with initial cohorts of 194 patients with local allergic rhinitis and 130 healthy controls was designed to answer this question. After 10 years of follow-up, 176 patients remained, and skin prick tests and/or serum-specific IgE became positive in only 9.7 percent of those with local allergic rhinitis and in 7.8 percent of controls. The authors interpreted these findings as indicating that local allergic rhinitis is a separate condition from classic allergic rhinitis and
         <strong>
          not
         </strong>
         simply a precursor phase of this disorder [
         <a href="#rid58">
          58,59
         </a>
         ].
        </p>
        <p>
         On the other hand, other researchers (using similar techniques) were either unable to demonstrate consistent responses to nasal allergen challenge in patients with NAR [
         <a href="#rid60">
          60
         </a>
         ] or found the same responses in healthy controls [
         <a href="#rid61">
          61
         </a>
         ]. These findings challenge the concept that NAR results from a localized, IgE-mediated mechanism. An alternative explanation could be nonspecific hyperreactivity of the nasal mucosa due to inflammation from another etiology.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rhinitis, in both its allergic and nonallergic forms, affects 10 to 40 percent of the population in industrialized countries [
         <a href="#rid62">
          62
         </a>
         ]. Pure chronic NAR may be responsible for anywhere from 17 to 52 percent of all cases of rhinitis in adults [
         <a href="#rid4">
          4,63-70
         </a>
         ]. The prevalence of NAR in children is less well studied [
         <a href="#rid71">
          71-74
         </a>
         ]. Much of the data utilized to establish the prevalence of chronic NAR have been gathered from allergy specialty practices, although there have been some community-based epidemiologic surveys [
         <a href="#rid63">
          63-67,75,76
         </a>
         ].
        </p>
        <p>
         The prevalence of pure NAR underestimates the impact of this condition since it coexists with allergic rhinitis in a substantial subset of patients [
         <a href="#rid68">
          68
         </a>
         ]. Patients with both conditions have been described as having "mixed" rhinitis, although they are generally classified as allergic since there is no established United States diagnostic code for "mixed" allergic and nonallergic disease.
        </p>
        <p>
         In addition, in the presence of allergen-specific IgE, it is difficult to establish the existence of concomitant NAR. The Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology has estimated that, taking this underestimation into account, approximately 50 percent of patients presenting with rhinitis may have the nonallergic form (alone or as mixed disease) [
         <a href="#rid68">
          68
         </a>
         ]. Based upon a survey of American allergists, 34 percent of 975 rhinitis patients were identified as having the "mixed" form of rhinitis [
         <a href="#rid67">
          67
         </a>
         ]. Extrapolating these data to the overall incidence of rhinitis in the United States revealed that NAR may affect as many as 17 million Americans and that an additional 22 million may suffer from the "mixed form" of rhinitis [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1685189">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         NAR presents later in life than allergic rhinitis, with 70 percent of patients presenting after 20 years of age [
         <a href="#rid66">
          66,77
         </a>
         ]. In comparison, the onset of allergic rhinitis usually occurs before age 20 (and often in childhood).
        </p>
        <p>
         Women make up the majority of patients in most studies, so there may be a female predominance [
         <a href="#rid64">
          64,78
         </a>
         ].
        </p>
        <p>
         Rhinitis of older adults (also called senile rhinitis) is a term used to describe NAR in older patients. It is characterized by prominent rhinorrhea and aggravated by eating and environmental factors [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Prominent rhinorrhea without other symptoms'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical history is the
         <strong>
          most
         </strong>
         <strong>
          important
         </strong>
         tool used to make the distinction between NAR and other forms of rhinitis.
        </p>
        <p class="headingAnchor" id="H703760442">
         <span class="h2">
          Compared with allergic rhinitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with allergic rhinitis, features that are helpful in correctly identifying NAR include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most frequent and prominent clinical manifestations of NAR are nasal blockage and postnasal drip [
         <a href="#rid80">
          80
         </a>
         ]. In contrast, patients with allergic rhinitis report prominent eye symptoms, sneezing, and rhinorrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with NAR often cannot readily identify triggers, such as times of year when specific pollens are prevalent or exposure to animals. In contrast, most patients with allergic rhinitis can identify one or more triggers. (See
         <a class="local">
          'Characteristic triggers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms most commonly occur throughout the year (eg, perennial), although the condition may be exacerbated by weather conditions, particularly during the spring and fall [
         <a href="#rid81">
          81
         </a>
         ]. Symptoms in those with allergic disease usually show seasonal patterns, although some have perennial symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with NAR suffer from comorbidities, including asthma, chronic rhinosinusitis, otitis media, sleep disturbance, and declines in quality of life, similar to those with allergic rhinitis [
         <a href="#rid41">
          41,82
         </a>
         ]. Studies examining the relationship between NAR and asthma are reviewed in more detail below. (See
         <a class="local">
          'Relationship with asthma'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H578257771">
         <span class="h2">
          Characteristic triggers
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory irritants (eg, cigarette smoking, strong scents, and fragrances) are prominent inducers of symptoms, although this may be true for patients with longstanding allergic rhinitis also. Nonallergic rhinitis due to irritants in the workplace is a frequent (but sometimes overlooked) cause of occupational rhinitis [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">
          "Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis", section on 'Increasing sensitivity over time'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weather changes (eg, fluctuations in temperature, humidity, and/or barometric pressure) affect many patients with NAR. In a study using a unique environmental exposure chamber designed to simulate various weather conditions, 37 subjects were challenged with cold, dry air, and temperature changes [
         <a href="#rid84">
          84
         </a>
         ]. Nasal patency was assessed with acoustic rhinometry and rhinorrhea by measurement of nasal secretions. In addition, subjective measures of nasal symptoms were also evaluated. Significant symptoms with objective confirmation were induced in response to these simulated weather changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heated or spicy foods induce watery rhinorrhea in patients with the syndrome of gustatory rhinitis, which can be considered a subtype of NAR. Food triggers are more common in older adults, and gustatory rhinitis and rhinitis of older adults overlap [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Prominent rhinorrhea without other symptoms'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4249291176">
         <span class="h2">
          Relationship with asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         NAR, like allergic rhinitis, is associated with asthma and is a significant risk factor for the development of asthma. Some studies have found that NAR confers a lower risk of asthma compared with allergic rhinitis [
         <a href="#rid85">
          85
         </a>
         ], while others have found similar rates of asthma development [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         There may be subsets of patients with NAR that are at particularly elevated risk for asthma. Those with inflammatory NAR with increased nasal eosinophilia appear to be at greater risk for the development of asthma than patients with NAR without eosinophilia [
         <a href="#rid13">
          13,88,89
         </a>
         ]. Those with eosinophilia not only have a comparatively elevated risk for asthma but also a greater risk for the development of chronic rhinosinusitis with nasal polyposis and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         sensitivity. (See
         <a class="medical medical_review" href="/z/d/html/520.html" rel="external">
          "Aspirin-exacerbated respiratory disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          PHYSICAL EXAM
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nasal turbinates can appear boggy and edematous in both allergic rhinitis and NAR. The mucosal tissue is more often erythematous in nonallergic disease as compared with the pale-bluish hue or pallor seen with allergic rhinitis. However, none of these findings are diagnostic, and the mucosa can even appear relatively normal, particularly in older patients.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of chronic NAR is based on a characteristic history and physical examination, combined with the absence of evidence for clinical allergy to aeroallergens. It is therefore a diagnosis of exclusion. However, in practical terms, allergy testing is not essential to making a presumptive initial diagnosis of NAR and beginning therapy. In addition, allergic rhinitis and NAR can coexist, and, in such cases, it may only become clear that the patient has both disorders in retrospect once an effective combination of medications is found.
        </p>
        <p class="headingAnchor" id="H4107301">
         <span class="h2">
          Referral for allergy testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is not necessary to perform allergy testing before making a presumptive diagnosis of NAR and initiating treatment as previously mentioned. However, if the patient is not experiencing adequate improvement, then testing for allergy is indicated to clarify the etiology.
        </p>
        <p>
         Allergy testing can be accomplished either through skin testing or with blood tests. In general, skin testing with aeroallergens is the more sensitive and specific of the two methods, but it should only be performed by an allergy expert, and, thus, referral is required. (See
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease"
         </a>
         .)
        </p>
        <p>
         The other method of identifying allergic sensitivities is immunoassays to detect allergen-specific IgE antibodies in the serum. These tests are widely available and require no patient preparation (such as discontinuation of medications). IgE immunoassays provide similar information as that obtained with allergen skin tests, although they are variably more expensive and less sensitive for the diagnosis of allergy to inhalant allergens compared with skin tests. (See
         <a class="medical medical_review" href="/z/d/html/5540.html" rel="external">
          "Overview of in vitro allergy tests", section on 'Accuracy'
         </a>
         .)
        </p>
        <p>
         In evaluating patients for allergy, clinicians should be mindful that a positive skin test for allergy or a positive in vitro test by itself does not prove that the patient is allergic to that substance. The result must be consistent with the clinical history, with symptoms occurring during the appropriate season, or upon exposure. (See
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">
          "Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
         The use of limited panels of IgE immunoassays in the primary care setting has been evaluated in the diagnosis and management of rhinitis. Such testing can improve diagnostic accuracy and/or management when skin testing is not easily obtained [
         <a href="#rid90">
          90-92
         </a>
         ]. These panels typically test for IgE antibodies to common seasonal and perennial allergens [
         <a href="#rid91">
          91,93
         </a>
         ]. Some perennial allergens are relevant to almost all populations (eg, dust mites, animal danders). However, other allergens (pollens and molds) are relevant to specific geographic areas. A logical approach for determining which allergens should be included would involve consulting a local allergy expert initially to identify a limited number of allergens that are important in that area [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of chronic NAR includes several other forms of rhinitis, as well as laryngopharyngeal reflux.
        </p>
        <p class="headingAnchor" id="H1949203">
         <span class="h2">
          Other forms of rhinitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various other causes of rhinitis should be excluded  (
         <a class="graphic graphic_table graphicRef75862" href="/z/d/graphic/75862.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhinitis medicamentosa (due to topical decongestants) and nasal dysfunction related to systemic medications, such as some erectile dysfunction drugs, medications for prostatic hypertrophy, and some antihypertensives  (
         <a class="graphic graphic_table graphicRef75862" href="/z/d/graphic/75862.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Management of rhinitis medicamentosa'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occupational rhinitis (allergic and irritant) (see
         <a class="medical medical_review" href="/z/d/html/7529.html" rel="external">
          "Occupational rhinitis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrophic rhinitis, which is characterized by chronic nasal congestion, crusting of secretions, halitosis, and a thin, erythematous mucosa on nasal examination (see
         <a class="medical medical_review" href="/z/d/html/7531.html" rel="external">
          "Atrophic rhinosinusitis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal polyposis, which is often characterized by severe congestion or obstruction and reduced or absent sense of smell (see
         <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">
          "Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'CRS with nasal polyposis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhinitis in association with hormonal changes of pregnancy, lactation, hypothyroidism, and acromegaly (see
         <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">
          "An overview of rhinitis", section on 'Other causes of rhinitis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11252036">
         <span class="h3">
          Management of rhinitis medicamentosa
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physical examination in patients with rhinitis medicamentosa often reveals swollen, red nasal mucous membranes. Diagnosis most heavily relies upon the history of use of a causative medication. In some patients, even several days of regular use of decongestant sprays leads to rebound nasal congestion as the medication wears off, prompting patients to administer the medicine more frequently to obtain relief. This begins a vicious cycle of nasal congestion both caused and temporarily relieved by the medication with escalating use and eventual dependency [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         Treatment of rhinitis medicamentosa begins with withdrawal of the causative medication. In addition, an intranasal corticosteroid (INCS) is usually required to reduce symptoms while patients discontinue the culprit decongestant [
         <a href="#rid96">
          96-99
         </a>
         ]. It is important to counsel patients that nasal congestion will probably worsen temporarily as the offending medication is stopped so that this is not interpreted as treatment failure. Intranasal
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         was shown in a small randomized trial of 19 patients to be effective in countering rebound nasal congestion in this setting [
         <a href="#rid95">
          95
         </a>
         ]. Topical INCS achieve high concentrations of the drug in the affected mucosa and are the most appropriate long-term therapy. Complete recovery can take as long as one year in cases of long-term overuse [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p>
         A brief course of oral glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , 0.5 mg per kg for five days) has also been proposed for treatment during withdrawal in some case reports. This is helpful when nasal congestion is sufficiently severe that topical therapies cannot penetrate up into the nose. However, this is not necessary in most patients.
        </p>
        <p class="headingAnchor" id="H1949210">
         <span class="h2">
          Laryngopharyngeal reflux
         </span>
         <span class="headingEndMark">
          —
         </span>
         Isolated postnasal irritation and excessive phlegm can also result from reflux of gastric fluids with or without esophageal symptoms noticeable to the patient, which is a condition referred to as laryngopharyngeal reflux. In a randomized trial of 75 patients with isolated postnasal drip, sinus disease and allergic rhinitis were excluded with a sinus computed tomography (CT) and either skin testing or in vitro test allergy testing, respectively [
         <a href="#rid102">
          102
         </a>
         ]. Patients were assigned to either
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         (30 mg twice daily) or placebo for 16 weeks. There was statistically significant improvement in symptoms in the group receiving lansoprazole at 8 and 16 weeks, which persisted at least to two months. The responders were not distinguishable from nonresponders either by pH or impedance monitoring at the start of the study. (See
         <a class="medical medical_review" href="/z/d/html/6852.html" rel="external">
          "Laryngopharyngeal reflux in adults: Evaluation, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic NAR are generally less responsive to pharmacologic therapy than those with allergic rhinitis [
         <a href="#rid8">
          8,103
         </a>
         ]. Specifically, most find oral antihistamines unhelpful [
         <a href="#rid104">
          104,105
         </a>
         ]. However, two classes of medications are useful in treating the total symptom complex of chronic NAR [
         <a href="#rid67">
          67,106-116
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intranasal corticosteroids (INCS)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intranasal antihistamines
        </p>
        <p>
        </p>
        <p>
         Patients with mild disease may be adequately treated with either INCS or intranasal antihistamine monotherapy. There are no studies specifically comparing the two therapies in a head-to-head manner.
        </p>
        <p>
         Patients who are very symptomatic tend to respond better to combination therapy [
         <a href="#rid117">
          117
         </a>
         ]. We generally use full-strength dosing for both agents and emphasize to patients that the medications should be used on a daily basis regardless of the presence or absence of symptoms. (See
         <a class="local">
          'Combination therapy'
         </a>
         below.)
        </p>
        <p>
         In addition to these agents,
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         has been approved specifically to treat the symptom of rhinorrhea in chronic NAR [
         <a href="#rid118">
          118,119
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H150418036">
         <span class="h3">
          Combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been our clinical experience that the combination of INCS and intranasal antihistamines is more effective than either agent alone. This has been demonstrated in patients with seasonal allergic rhinitis [
         <a href="#rid120">
          120
         </a>
         ], although it has not been specifically studied in chronic NAR:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A combination spray containing
         <a class="drug drug_general" data-topicid="83881" href="/z/d/drug information/83881.html" rel="external">
          azelastine-fluticasone
         </a>
         is available in the United States and is approved for children six years of age and older and adults for seasonal allergic rhinitis. The dose is one actuation per nostril, twice daily. This combination product has been studied in patients with seasonal allergic rhinitis and has been shown to be superior to single treatment with either agent alone [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another combination is
         <a class="drug drug_general" data-topicid="134840" href="/z/d/drug information/134840.html" rel="external">
          olopatadine-mometasone
         </a>
         , which is approved for patients ≥12 years of age. The dose is two sprays per nostril twice daily. Combination therapy can also be achieved with two separate sprays.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the INCS component, we usually begin with full-strength dosing. Multiple preparations are available  (
         <a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Options for an intranasal antihistamine spray include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          Azelastine
         </a>
         0.15%, one to two actuations per nostril twice daily and decreasing the dose as symptoms improve. Many patients' symptoms are controlled with once-daily dosing. Azelastine is also available in a 0.1% preparation, as well as a generic preparation that is dosed two actuations each nostril twice daily in adults and one actuation twice daily in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">
          Olopatadine
         </a>
         hydrochloride nasal spray (0.06%) that is dosed two actuations twice daily in adults and children &gt;12 and one actuation twice daily for children ≤11 years.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Efficacy of corticosteroid sprays
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a systematic review of 18 trials comparing monotherapy with INCS to placebo for all types of NAR, the strength of the evidence for benefit beyond the first few months was low to very low [
         <a href="#rid121">
          121
         </a>
         ]. Individual trials that demonstrated benefit estimated the effect size to be small to moderate.
        </p>
        <p>
         It is possible that specific subtypes of NAR are more or less responsive to INCS than others. A multicenter, randomized trial assessed the effects of
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         furoate on a subset of patients with symptoms that were triggered predominantly by changes in weather and temperature and found no difference compared with placebo [
         <a href="#rid122">
          122
         </a>
         ]. Thus, although patients with NAR as a group derive some benefit from INCS, there are clearly important subgroups of nonresponders that require further study.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Efficacy of antihistamine sprays
         </span>
         <span class="headingEndMark">
          —
         </span>
         As monotherapy,
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         has been shown to be effective in prospective studies [
         <a href="#rid110">
          110,123
         </a>
         ]. As an example, in two multicenter, randomized, open-label trials, approximately 80 to 85 percent of more than 200 subjects with chronic NAR responded favorably to azelastine [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
         The improvement in symptoms with
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         is likely due to antiinflammatory actions. Azelastine reduces eosinophil activation and adhesion molecule expression and suppresses inflammatory cytokine generation [
         <a href="#rid114">
          114,115,124
         </a>
         ]. Azelastine may also reduce neurogenic excitation from olfactory stimuli. In the previously mentioned study in which subjects with NAR were exposed to pleasant and unpleasant odors, the administration of azelastine significantly attenuated exaggerated blood flow to odor-sensitive regions of the brain as assessed by magnetic resonance imaging (MRI) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">
          Olopatadine
         </a>
         and
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         (0.1%) were compared for the treatment of NAR in a multicenter, randomized parallel group study lasting 14 days [
         <a href="#rid125">
          125
         </a>
         ]. Both reduced congestion, rhinorrhea, postnasal drip, and sneezing, and there were no statistically significant differences between their effects. In addition, there was no difference in the side effect profile of the two agents, although both medicines have a bitter taste. In another placebo-controlled study, olopatadine reduced the response to hyperosmolar challenge in patients with prominent vasomotor symptoms [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Prominent rhinorrhea without other symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         When rhinorrhea is the dominant symptom or the only symptom, as in gustatory rhinitis or rhinitis of older adults,
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         (0.03%) nasal spray is recommended [
         <a href="#rid3">
          3,36,127
         </a>
         ]. Ipratropium is usually employed at a dose of two sprays to each nostril three times per day. Alternatively, it can also be used as needed or prior to exposures that cause rhinorrhea, such as before cold air exposure or eating. This medication is also available in a concentration of 0.06%, although this strength is intended for short-term use only (eg, treatment of rhinorrhea associated with the common cold). Two multicenter, placebo-controlled trials demonstrated the effectiveness of ipratropium to control rhinorrhea [
         <a href="#rid118">
          118,119
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The administration of
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         nasal spray (0.03%) for one year among 285 patients with perennial NAR resulted in significant improvement in rhinorrhea, as well as a decreased need for additional medications to control symptoms [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 253 patients with perennial NAR,
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         nasal spray significantly reduced rhinorrhea versus that observed with placebo [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Adjunctive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjunctive therapies that are helpful in some patients include oral decongestants, nasal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         sprays and irrigations, and oral antihistamines. Studies of antileukotriene drugs and intranasal chromones in the treatment of NAR are lacking.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral decongestants
         </strong>
         – An oral decongestant, such as
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         , can be added to the treatment regimen, unless symptoms related to prostatic hyperplasia or hypertension preclude their use. The usual dosing of pseudoephedrine is 30 or 60 mg orally, up to three times daily on symptomatic days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          Phenylephrine
         </a>
         hydrochloride is also widely available, but it is less effective for the treatment of rhinitis symptoms and may not be superior to placebo at the 10 mg dose that is commonly available without prescription [
         <a href="#rid128">
          128,129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are no specific studies examining the clinical efficacy of decongestants for this NAR. Such agents are employed as needed only for congestion not responsive to the use of either the nasal corticosteroid,
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         , or a combination of both.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nasal
         </strong>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         <strong>
          irrigation
         </strong>
         – Daily nasal lavage or nasal saline sprays can also be useful. These interventions are particularly helpful for symptoms of postnasal drainage. They can be used immediately prior to INCS or
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         so that the mucosa is freshly cleansed when the medications are applied  (
         <a class="graphic graphic_table graphicRef71059" href="/z/d/graphic/71059.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nasal lavage is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed. A large body of observational reports and one prospective, controlled clinical study has found that nasal lavage is effective in NAR as well as chronic rhinosinusitis [
         <a href="#rid130">
          130
         </a>
         ]. In the only prospective study, the use of nasal irrigation significantly improved 23 of 30 nasal symptoms [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A variety of over-the-counter devices including bulb syringes and bottle sprayers are effective, provided the system delivers an adequate volume of solution (&gt;200 mL per side) into the nose. Patients can make their own solutions or buy commercially prepared kits. Nasal lavage with warmed
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         can be performed as needed only, daily at baseline, or twice daily for increased symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One nasal lavage device, Navage (brand name), combines a forceful automatic spray into one nostril with simultaneous suction from the opposite nostril. We have found this device to be effective, and we employ it regularly in our practice.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intranasal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         sprays have also been found effective for symptoms of chronic NAR, including relieving postnasal drip, sneezing, and congestion [
         <a href="#rid67">
          67,132
         </a>
         ]. Saline sprays are somewhat less effective than larger-volume nasal lavage, although they may be more convenient for some patients [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral antihistamines
         </strong>
         – Clinical experience and limited data suggest that the newer, nonsedating H1 antihistamines are not as effective in NAR compared with allergic rhinitis [
         <a href="#rid104">
          104,105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Older, first-generation H1 antihistamines (eg,
         <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">
          chlorpheniramine
         </a>
         ) have anticholinergic properties that can be helpful to some patients with persistent and bothersome postnasal drip and/or anterior rhinorrhea despite the above therapies [
         <a href="#rid134">
          134
         </a>
         ]. However, these medications are sedating and have other disadvantages that are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">
          "Pharmacotherapy of allergic rhinitis", section on 'Oral antihistamines'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Role of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several surgical approaches have been used in patients with severe chronic NAR [
         <a href="#rid127">
          127,135-138
         </a>
         ]. These have been reported as uncontrolled case series. Such interventions may be helpful in patients with difficult symptoms that are refractory to multiple therapies (eg, corticosteroid nasal spray in combination with
         <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">
          azelastine
         </a>
         and/or decongestants and/or
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         nasal spray). Six to 12 months of medical management should be allowed before surgical options are considered. Studies of efficacy are lacking.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kinetic oscillation stimulation (KOS) appears to stabilize the autonomic dysregulation characteristic of many forms of NAR. It utilizes a balloon placed in the nasal cavity. The balloon is pulsed with air and vibrated for 10 minutes per side. In one study, a single treatment could provide subjective relief for several months, and there were no major adverse effects [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A turbinectomy can be performed when congestion is predominant. With this technique, there has been concern about the destruction and/or elimination of the mucosal surface. However, laser turbinectomy has been reported to preserve normal nasal cytology as well as normal ciliary activity [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A number of other surgical procedures have been tried in the past, including vidian nerve resection, electrocoagulation of anterior ethmoidal nerve, sphenopalatine ganglion block, and others [
         <a href="#rid138">
          138,140,141
         </a>
         ]. None of these techniques have been shown to have long-term benefits, and the potential risks (eg, persistent pain) have to be considered carefully since they may outweigh any possible benefits. However, this is an area of ongoing research, and future therapies may emerge. For example, temperature-controlled radiofrequency neurolysis has been successfully employed for ablation of the posterior nasal nerve area to produce a significant reduction in symptoms in a group of patients deemed refractory to medication treatment. Relief persisted for 52 weeks, and there were no significant side effects [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1689286">
         <span class="h2">
          Alternative therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         has been shown to reduce the symptoms of NAR, but irritation of the nasal mucosa was a limiting factor [
         <a href="#rid143">
          143-145
         </a>
         ]. Subsequently, a randomized trial of 42 patients with a significant component of NAR evaluated the effects of a diluted capsaicin nasal spray to which eucalyptol was added to reduce the burning sensation caused by capsaicin [
         <a href="#rid146">
          146
         </a>
         ]. After two weeks of therapy with this preparation (dosed up to 12 actuations daily), patients reported significant improvements in total nasal symptom scores compared with placebo and good tolerability. This preparation is available without a prescription [
         <a href="#rid147">
          147
         </a>
         ]. A 2015 Cochrane review concluded that "capsaicin may be an option in the treatment of idiopathic nonallergic rhinitis" based on low-quality evidence [
         <a href="#rid148">
          148
         </a>
         ]. We do not have extensive experience with this product.
        </p>
        <p>
         Other alternative and complementary therapies have been evaluated, such as acupuncture and topical
         <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">
          silver nitrate
         </a>
         , although they cannot be recommended at this time.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Follow-up care
         </span>
         <span class="headingEndMark">
          —
         </span>
         We follow patients receiving chronic therapy for rhinitis every 3 to 12 months, depending upon the severity and nature of the symptoms. The medications regimen can be reduced in some patients over time. However, in most patients, some medication is usually needed on a daily and long-term basis.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic NAR is a persistent condition in the majority of patients. In one study, 180 patients with NAR were reevaluated three to seven years after diagnosis [
         <a href="#rid149">
          149
         </a>
         ]. Fifty-two percent reported worsening symptoms. There was a statistically significant increase in the percentage of patients who had developed asthma (32 to 55 percent), and 11 percent had decrements in lung function compared with their initial evaluation. The relationship between NAR and asthma is reviewed above. (See
         <a class="local">
          'Relationship with asthma'
         </a>
         above.)
        </p>
        <p>
         In addition, 24 percent had developed allergen-specific IgE (most commonly to dust mite and animal epithelia). Thus, over time, chronic NAR may involve the lower airways in some patients, leading to asthma, and can also progress to allergic rhinitis.
        </p>
        <p class="headingAnchor" id="H874347618">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109564.html" rel="external">
          "Society guideline links: Rhinitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/380.html" rel="external">
          "Patient education: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Chronic nonallergic rhinitis (NAR) is a syndrome in which some combination of sneezing, rhinorrhea, nasal congestion, and postnasal drainage is present over time in the absence of a specific allergic etiology. The pathogenesis is not well characterized. Other terms for this condition include vasomotor rhinitis, idiopathic rhinitis, nonallergic-noninfectious rhinitis, and intrinsic rhinitis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Definition'
         </a>
         above and
         <a class="local">
          'Theories of pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – As many as 50 percent of patients presenting with rhinitis may have NAR, either alone or in combination with allergic rhinitis or other forms of rhinitis. (See
         <a class="local">
          'Prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Compared with allergic rhinitis, NAR has a later age of onset (usually after age 20 years) and more prominent nasal congestion and postnasal drainage. Symptoms of allergic conjunctivitis are absent. Patients often identify weather conditions or nonspecific respiratory irritants (eg, cigarette smoke) as exacerbating factors. Gustatory rhinitis is a subtype of NAR that presents as watery rhinorrhea in response to eating, particularly upon ingestion of heated or spicy foods (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Diagnosis is based upon characteristic historic features, physical exam findings, and the absence of evidence of sensitivity to aeroallergens. It is a diagnosis of exclusion, although it may coexist with other forms of rhinitis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of NAR includes several other forms of rhinitis  (
         <a class="graphic graphic_table graphicRef75862" href="/z/d/graphic/75862.html" rel="external">
          table 1
         </a>
         ), as well as laryngopharyngeal reflux. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment options
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with mild symptoms of NAR, we suggest monotherapy with either an intranasal corticosteroid (INCS) or an intranasal antihistamine spray (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with moderate-to-severe symptoms, we suggest combination therapy with
         <strong>
          both
         </strong>
         INCS  (
         <a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">
          table 2
         </a>
         ) and intranasal antihistamines, rather than monotherapy with either agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We find that most patients require both agents daily for adequate symptom control. We start with full-strength doses of both agents and reduce the doses over time as symptoms improve. Combination sprays containing both corticosteroid and antihistamine are also available (ie,
         <a class="drug drug_general" data-topicid="83881" href="/z/d/drug information/83881.html" rel="external">
          azelastine-fluticasone
         </a>
         and
         <a class="drug drug_general" data-topicid="134840" href="/z/d/drug information/134840.html" rel="external">
          olopatadine-mometasone
         </a>
         ). (See
         <a class="local">
          'Combination therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with NAR and prominent nasal congestion that is refractory to INCS  (
         <a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">
          table 2
         </a>
         ), intranasal antihistamines, or a combination of both, we suggest adding over-the-counter oral decongestants on an as-needed basis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          Pseudoephedrine
         </a>
         is commonly employed but should be used with caution in patients with hypertension. (See
         <a class="local">
          'Adjunctive therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Daily nasal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         irrigation is a helpful adjunctive therapy for patients with NAR and other forms of rhinitis who find the maneuver comfortable  (
         <a class="graphic graphic_table graphicRef71059" href="/z/d/graphic/71059.html" rel="external">
          table 3
         </a>
         ). Regular use of over-the-counter nasal saline sprays may also benefit some patients. (See
         <a class="local">
          'Adjunctive therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with prominent watery rhinorrhea without other symptoms, we suggest
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         nasal spray (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Isolated rhinorrhea is typical of gustatory rhinitis and rhinitis of older adults. (See
         <a class="local">
          'Prominent rhinorrhea without other symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – NAR tends to be a persistent condition. Over time, it may involve the lower airways in some patients, leading to asthma, and can also progress to allergic rhinitis. (See
         <a class="local">
          'Prognosis'
         </a>
         above and
         <a class="local">
          'Evidence for a localized allergic response'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Blom HM, Godthelp T, Fokkens WJ, et al. Mast cells, eosinophils and IgE-positive cells in the nasal mucosa of patients with vasomotor rhinitis. An immunohistochemical study. Eur Arch Otorhinolaryngol 1995; 252 Suppl 1:S33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powe DG, Huskisson RS, Carney AS, et al. Evidence for an inflammatory pathophysiology in idiopathic rhinitis. Clin Exp Allergy 2001; 31:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellings PW, Klimek L, Cingi C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2017; 72:1657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bousquet J, Fokkens W, Burney P, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy 2008; 63:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol 2020; 146:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rijswijk JB, Blom HM, Fokkens WJ. Idiopathic rhinitis, the ongoing quest. Allergy 2005; 60:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numata T, Konno A, Hasegawa S, et al. Pathophysiological features of the nasal mucosa in patients with idiopathic rhinitis compared to allergic rhinitis. Int Arch Allergy Immunol 1999; 119:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blom HM, Godthelp T, Fokkens WJ, et al. The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis. J Allergy Clin Immunol 1997; 100:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MALCOMSON KG. The vasomotor activities of the nasal mucous membrane. J Laryngol Otol 1959; 73:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones AS, Lancer JM. Vasomotor rhinitis. Br Med J (Clin Res Ed) 1987; 294:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilde AD, Cook JA, Jones AS. The nasal response to isometric exercise. Clin Otolaryngol Allied Sci 1995; 20:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf G. [New aspects in the pathogenesis and therapy of hyperreflexive rhinopathy]. Laryngol Rhinol Otol (Stuttg) 1988; 67:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moneret-Vautrin DA, Hsieh V, Wayoff M, et al. Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. Ann Allergy 1990; 64:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baraniuk JN. Neural control of human nasal secretion. Pulm Pharmacol 1991; 4:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundblad L, Hua XY, Lundberg JM. Mechanisms for reflexive hypertension induced by local application of capsaicin and nicotine to the nasal mucosa. Acta Physiol Scand 1984; 121:277.
          </a>
         </li>
         <li class="breakAll">
          Lacrois JS, Pochon N, Lundberg JM. Increased concentration of sensory neuropeptide in the nasal mucosa from patients with nonallergic chronic rhinitis. In: The new frontier of otorhinolaryngology in Europe, Passall D (Ed), Monduzzi Editore, Sorrento, Italy 1992. p.59.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borson DB. Roles of neutral endopeptidase in airways. Am J Physiol 1991; 260:L212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotter CM, Hall GH, Salter DM, Wilson JA. Histology of mucous membrane of human inferior nasal concha. Clin Anat 1990; 3:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger G, Goldberg A, Ophir D. The inferior turbinate mast cell population of patients with perennial allergic and nonallergic rhinitis. Am J Rhinol 1997; 11:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachert C, Prohaska P, Pipkorn U. IgE-positive mast cells on the human nasal mucosal surface in response to allergen exposure. Rhinology 1990; 28:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otsuka H, Inaba M, Fujikura T, Kunitomo M. Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis: studies of nasal scrapings and their dispersed cells. J Allergy Clin Immunol 1995; 96:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fokkens WJ, Godthelp T, Holm AF, et al. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study. Clin Exp Allergy 1992; 22:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ying S, Durham SR, Jacobson MR, et al. T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 82:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varney VA, Jacobson MR, Sudderick RM, et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis 1992; 146:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godthelp T, Holm AF, Fokkens WJ, et al. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study. J Allergy Clin Immunol 1996; 97:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connell JT. Nasal mastocytosis. J Allergy 1969; 43:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drake-Lee AB, Moriarty B, Smallman LA. Mast cell numbers in the mucosa of the inferior turbinate in patients with perennial allergic rhinitis: a light microscopic study. J Laryngol Otol 1991; 105:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruhno J, Howie K, Anderson M, et al. The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent. Allergy 1990; 45:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malm L, Wihl JA, Lamm CJ, Lindqvist N. Reduction of metacholine-induced nasal secretion by treatment with a new topical steroid in perennial non-allergic rhinitis. Allergy 1981; 36:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Menz G, Ying S, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996; 153:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroegel C, Jäger L, Walker C. Is there a place for intrinsic asthma as a distinct immunopathological entity? Eur Respir J 1997; 10:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Togias AG, Proud D, Lichtenstein LM, et al. The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air. Am Rev Respir Dis 1988; 137:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000; 55 Suppl 64:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Hastings L, Boespflug EL, et al. Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine. Ann Allergy Asthma Immunol 2011; 106:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raphael G, Raphael MH, Kaliner M. Gustatory rhinitis: a syndrome of food-induced rhinorrhea. J Allergy Clin Immunol 1989; 83:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papon JF, Brugel-Ribere L, Fodil R, et al. Nasal wall compliance in vasomotor rhinitis. J Appl Physiol (1985) 2006; 100:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iguchi Y, Yao K, Okamoto M. A characteristic protein in nasal discharge differentiating non-allergic chronic rhinosinusitis from allergic rhinitis. Rhinology 2002; 40:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maselli Del Giudice A, Barbara M, Russo GM, et al. Cell-mediated non-allergic rhinitis in children. Int J Pediatr Otorhinolaryngol 2012; 76:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelardi M, Luigi Marseglia G, Licari A, et al. Nasal cytology in children: recent advances. Ital J Pediatr 2012; 38:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poletti D, Iannini V, Casolari P, et al. Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study. J Inflamm (Lond) 2016; 13:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai J, Guan S, Mai Z, Zhang S. [Analysis of the level and significance of IL-16 and IL-17 in nasal secretion and in serum of patients with allergic rhinitis and non-allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2014; 28:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Branicka O, Jura-Szołtys E, Rogala B, Glück J. sCD48 is elevated in non-allergic but not in allergic persistent rhinitis. Immunopharmacol Immunotoxicol 2021; 43:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Che Y, Wang N, Ma Q, et al. Microbial characterization of the nasal cavity in patients with allergic rhinitis and non-allergic rhinitis. Front Cell Infect Microbiol 2023; 13:1166389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KleinJan A, Vinke JG, Severijnen LW, Fokkens WJ. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J 2000; 15:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Romero JJ, López S, et al. Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clin Immunol 2007; 119:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Fernández J, López S, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. J Allergy Clin Immunol 2009; 124:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Campo P, Togias A, et al. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol 2012; 129:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smurthwaite L, Walker SN, Wilson DR, et al. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur J Immunol 2001; 31:3422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smurthwaite L, Durham SR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002; 2:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamizan AW, Rimmer J, Alvarado R, et al. Positive allergen reaction in allergic and nonallergic rhinitis: a systematic review. Int Forum Allergy Rhinol 2017; 7:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng KJ, Zhou ML, Xu YY, Zhou SH. The role of local allergy in the nasal inflammation. Eur Arch Otorhinolaryngol 2017; 274:3275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Campo P, Herrera R, et al. Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis. J Allergy Clin Immunol 2011; 128:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Campo P, Galindo L, et al. Prevalence and clinical relevance of local allergic rhinitis. Allergy 2012; 67:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klimek L, Bardenhewer C, Spielhaupter M, et al. [Local allergic rhinitis to Alternaria alternata : Evidence for local IgE production exclusively in the nasal mucosa]. HNO 2015; 63:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klimek L, von Bernus L, Pfaar O. [Local (exclusive) IgE production in the nasal mucosa. Evidence for local allergic rhinitis]. HNO 2013; 61:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campo P, Rondón C, Gould HJ, et al. Local IgE in non-allergic rhinitis. Clin Exp Allergy 2015; 45:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Campo P, Zambonino MA, et al. Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis. J Allergy Clin Immunol 2014; 133:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondon C, Campo P, Eguiluz-Gracia I, et al. Local allergic rhinitis is an independent rhinitis phenotype: The results of a 10-year follow-up study. Allergy 2018; 73:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wierzbicki DA, Majmundar AR, Schull DE, Khan DA. Multiallergen nasal challenges in nonallergic rhinitis. Ann Allergy Asthma Immunol 2008; 100:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelardi M, Guglielmi AV, Iannuzzi L, et al. Local allergic rhinitis: entopy or spontaneous response? World Allergy Organ J 2016; 9:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton E Jr. Chronic rhinitis in adults. J Allergy Clin Immunol 1988; 81:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980; 65:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enberg RN. Perennial nonallergic rhinitis: a retrospective review. Ann Allergy 1989; 63:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leynaert B, Bousquet J, Neukirch C, et al. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Togias A. Age relationships and clinical features of nonallergic rhinitis. J Allergy Clin Immunol 1990; 85:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol 2001; 86:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.
          </a>
         </li>
         <li class="breakAll">
          Togias AK. Nonallergic rhinitis. In: Allergic and nonallergic rhinitis: clinical aspects, Mygine N, Naclerio RM (Eds), Munksgaard, Copenhagen 1993. p.159.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol 2007; 19:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger WE, Schonfeld JE. Nonallergic rhinitis in children. Curr Allergy Asthma Rep 2007; 7:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chawes BL, Kreiner-Møller E, Bisgaard H. Objective assessments of allergic and nonallergic rhinitis in young children. Allergy 2009; 64:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erwin EA, Faust RA, Platts-Mills TA, Borish L. Epidemiological analysis of chronic rhinitis in pediatric patients. Am J Rhinol Allergy 2011; 25:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westman M, Stjärne P, Asarnoj A, et al. Natural course and comorbidities of allergic and nonallergic rhinitis in children. J Allergy Clin Immunol 2012; 129:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006; 61:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mølgaard E, Thomsen SF, Lund T, et al. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. Allergy 2007; 62:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Settipane RA. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc 2003; 24:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Settipane GA, Klein DE. Non allergic rhinitis: demography of eosinophils in nasal smear, blood total eosinophil counts and IgE levels. N Engl Reg Allergy Proc 1985; 6:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaliner MA. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). Immunol Allergy Clin North Am 2011; 31:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindberg S, Malm L. Comparison of allergic rhinitis and vasomotor rhinitis patients on the basis of a computer questionnaire. Allergy 1993; 48:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991; 46:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KS, Yum HY, Sheen YH, et al. Comorbidities and Phenotypes of Rhinitis in Korean Children and Adolescents: A Cross-sectional, Multicenter Study. Allergy Asthma Immunol Res 2017; 9:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shao Z, Bernstein JA. Occupational Rhinitis: Classification, Diagnosis, and Therapeutics. Curr Allergy Asthma Rep 2019; 19:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Salapatek AM, Lee JS, et al. Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model. Allergy Asthma Proc 2012; 33:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolla G, Guida G, Heffler E, et al. Diagnostic classification of persistent rhinitis and its relationship to exhaled nitric oxide and asthma: a clinical study of a consecutive series of patients. Chest 2007; 131:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chawes BL, Bønnelykke K, Kreiner-Møller E, Bisgaard H. Children with allergic and nonallergic rhinitis have a similar risk of asthma. J Allergy Clin Immunol 2010; 126:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelardi M, Iannuzzi L, Tafuri S, et al. Allergic and non-allergic rhinitis: relationship with nasal polyposis, asthma and family history. Acta Otorhinolaryngol Ital 2014; 34:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duran-Tauleria E, Vignati G, Guedan MJ, Petersson CJ. The utility of specific immunoglobulin E measurements in primary care. Allergy 2004; 59 Suppl 78:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansfield L, Hutteman HR, Tyson S, Enriquez A. A multiallergen and miniscreen can change primary care provider diagnosis and treatment of rhinitis. Am J Rhinol Allergy 2012; 26:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahlstedt S, Murray CS. In vitro diagnosis of allergy: how to interpret IgE antibody results in clinical practice. Prim Care Respir J 2006; 15:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2012; 67:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwong KY, Eghrari-Sabet JS, Mendoza GR, et al. The benefits of specific immunoglobulin E testing in the primary care setting. Am J Manag Care 2011; 17 Suppl 17:S447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006; 16:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passàli D, Salerni L, Passàli GC, et al. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf 2006; 5:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med 2005; 4:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doshi J. Rhinitis medicamentosa: what an otolaryngologist needs to know. Eur Arch Otorhinolaryngol 2009; 266:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallén H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy 1997; 27:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graf PM, Hallén H. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal. Am J Rhinol 1997; 11:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaezi MF, Hagaman DD, Slaughter JC, et al. Proton pump inhibitor therapy improves symptoms in postnasal drainage. Gastroenterology 2010; 139:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philip G, Togias AG. Nonallergic rhinitis. Pathophysiology and models for study. Eur Arch Otorhinolaryngol 1995; 252 Suppl 1:S27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullarkey MF. Eosinophilic nonallergic rhinitis. J Allergy Clin Immunol 1988; 82:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rinne J, Simola M, Malmberg H, Haahtela T. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002; 109:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondo H, Nachtigal D, Frenkiel S, et al. Effect of steroids on nasal inflammatory cells and cytokine profile. Laryngoscope 1999; 109:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malm L, Wihl JA. Intra-nasal beclomethasone dipropionate in vasomotor rhinitis. Acta Allergol 1976; 31:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wight RG, Jones AS, Beckingham E, et al. A double blind comparison of intranasal budesonide 400 micrograms and 800 micrograms in perennial rhinitis. Clin Otolaryngol Allied Sci 1992; 17:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small P, Black M, Frenkiel S. Effects of treatment with beclomethasone dipropionate in subpopulations of perennial rhinitis patients. J Allergy Clin Immunol 1982; 70:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banov CH, Lieberman P, Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 2001; 86:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995; 25:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pipkorn U, Berge T. Long-term treatment with budesonide in vasomotor rhinitis. Acta Otolaryngol 1983; 95:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takao A, Shimoda T, Matsuse H, et al. Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma. Ann Allergy Asthma Immunol 1999; 82:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996; 98:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997; 73:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamaoki J, Yamawaki I, Tagaya E, et al. Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways. Am J Physiol 1999; 276:L351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010; 105:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman J, Banov C, Boggs P, et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol 1995; 95:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronsky EA, Druce H, Findlay SR, et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol 1995; 95:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segboer C, Gevorgyan A, Avdeeva K, et al. Intranasal corticosteroids for non-allergic rhinitis. Cochrane Database Syst Rev 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs R, Lieberman P, Kent E, et al. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. Allergy Asthma Proc 2009; 30:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin 2005; 21:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman P. Intranasal antihistamines for allergic rhinitis: mechanism of action. Allergy Asthma Proc 2009; 30:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman P, Meltzer EO, LaForce CF, et al. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. Allergy Asthma Proc 2011; 32:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PK, Collins J. Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis. Am J Rhinol Allergy 2011; 25:e149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgalas C, Jovancevic L. Gustatory rhinitis. Curr Opin Otolaryngol Head Neck Surg 2012; 20:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatton RC, Winterstein AG, McKelvey RP, et al. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother 2007; 41:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009; 102:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey R, Hannan SA, Badia L, Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev 2007; :CD006394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spector SL. The placebo effect is nothing to sneeze at. J Allergy Clin Immunol 1992; 90:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pynnonen MA, Mukerji SS, Kim HM, et al. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg 2007; 133:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995; 95:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           el-Guindy A. Endoscopic transseptal vidian neurectomy. Arch Otolaryngol Head Neck Surg 1994; 120:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong Z. [Anterior ethmoidal electrocoagulation in the treatment of vasomotor rhinitis]. Zhonghua Er Bi Yan Hou Ke Za Zhi 1991; 26:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mladina R, Risavi R, Subaric M. CO2 laser anterior turbinectomy in the treatment of non-allergic vasomotor rhinopathia. A prospective study upon 78 patients. Rhinology 1991; 29:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes CM. Bilateral transnasal vidian neurectomy in the management of chronic rhinitis. J Laryngol Otol 1994; 108:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sainio S, Blomgren K, Laulajainen-Hongisto A, Lundberg M. The effect of single kinetic oscillation stimulation treatment on nonallergic rhinitis. Laryngoscope Investig Otolaryngol 2023; 8:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasanna A, Murthy PS. Vasomotor rhinitis and sphenopalatine ganglion block. J Pain Symptom Manage 1997; 13:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prianikov PD, Svistushkin VM, Egorov VI, et al. [The modern approach to the treatment of the patients presenting with vasomotor rhinitis with the use of the electrosurgical technique]. Vestn Otorinolaringol 2015; 80:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehmer D, McDuffie CM, Scurry WC Jr, et al. Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Rhinitis. Am J Rhinol Allergy 2022; 36:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blom HM, Van Rijswijk JB, Garrelds IM, et al. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. Clin Exp Allergy 1997; 27:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marabini S, Ciabatti PG, Polli G, et al. Beneficial effects of intranasal applications of capsaicin in patients with vasomotor rhinitis. Eur Arch Otorhinolaryngol 1991; 248:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fokkens W, Hellings P, Segboer C. Capsaicin for Rhinitis. Curr Allergy Asthma Rep 2016; 16:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Davis BP, Picard JK, et al. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol 2011; 107:171.
          </a>
         </li>
         <li class="breakAll">
          Marketed as Sinus Buster in the United States
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gevorgyan A, Segboer C, Gorissen R, et al. Capsaicin for non-allergic rhinitis. Cochrane Database Syst Rev 2015; :CD010591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondón C, Doña I, Torres MJ, et al. Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis. J Allergy Clin Immunol 2009; 123:1098.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7532 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7537565" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mast cells, eosinophils and IgE-positive cells in the nasal mucosa of patients with vasomotor rhinitis. An immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422150" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Evidence for an inflammatory pathophysiology in idiopathic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28474799" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18588549" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32707227" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Rhinitis 2020: A practice parameter update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16266377" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Idiopathic rhinitis, the ongoing quest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10474036" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathophysiological features of the nasal mucosa in patients with idiopathic rhinitis compared to allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9438480" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13631351" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The vasomotor activities of the nasal mucous membrane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3111614" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8548968" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The nasal response to isometric exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3050340" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : [New aspects in the pathogenesis and therapy of hyperreflexive rhinopathy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2346237" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1804491" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neural control of human nasal secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6475551" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mechanisms for reflexive hypertension induced by local application of capsaicin and nicotine to the nasal mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6475551" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mechanisms for reflexive hypertension induced by local application of capsaicin and nicotine to the nasal mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2018145" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Roles of neutral endopeptidase in airways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Histology of mucous membrane of human inferior nasal concha
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065349" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The inferior turbinate mast cell population of patients with perennial allergic and nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2251464" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : IgE-positive mast cells on the human nasal mucosal surface in response to allergen exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7560665" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis: studies of nasal scrapings and their dispersed cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1504893" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7927489" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1626799" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8613637" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nasal mastocytosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919342" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mast cell numbers in the mucosa of the inferior turbinate in patients with perennial allergic rhinitis: a light microscopic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2378440" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7015912" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Reduction of metacholine-induced nasal secretion by treatment with a new topical steroid in perennial non-allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10529782" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8665058" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9072976" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Is there a place for intrinsic asthma as a distinct immunopathological entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2449835" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11291780" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Allergic rhinitis: not purely a histamine-related disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21624753" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2643657" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Gustatory rhinitis: a syndrome of food-induced rhinorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16141379" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Nasal wall compliance in vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12012948" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A characteristic protein in nasal discharge differentiating non-allergic chronic rhinosinusitis from allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22939589" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cell-mediated non-allergic rhinitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23009215" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nasal cytology in children: recent advances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27493587" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25219212" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : [Analysis of the level and significance of IL-16 and IL-17 in nasal secretion and in serum of patients with allergic rhinitis and non-allergic rhinitis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34477021" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : sCD48 is elevated in non-allergic but not in allergic persistent rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37180436" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Microbial characterization of the nasal cavity in patients with allergic rhinitis and non-allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759442" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17337294" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796796" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516477" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Local allergic rhinitis: concept, pathophysiology, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745361" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Persistent IgE synthesis in the nasal mucosa of hay fever patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11918865" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Local IgE synthesis in allergic rhinitis and asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28727909" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Positive allergen reaction in allergic and nonallergic rhinitis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28625008" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The role of local allergy in the nasal inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21783237" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22913574" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prevalence and clinical relevance of local allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25929891" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : [Local allergic rhinitis to Alternaria alternata : Evidence for local IgE production exclusively in the nasal mucosa].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23241861" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : [Local (exclusive) IgE production in the nasal mucosa. Evidence for local allergic rhinitis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25495772" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Local IgE in non-allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24332860" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28833265" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Local allergic rhinitis is an independent rhinitis phenotype: The results of a 10-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18592815" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Multiallergen nasal challenges in nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27980704" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Local allergic rhinitis: entopy or spontaneous response?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3286737" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Chronic rhinitis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6101336" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2480728" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Perennial nonallergic rhinitis: a retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10452748" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Age relationships and clinical features of nonallergic rhinitis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11379801" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Update on nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9860027" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9860027" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17153005" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Epidemiology of rhinitis: allergic and nonallergic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17437681" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Nonallergic rhinitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19663868" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Objective assessments of allergic and nonallergic rhinitis in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22186247" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Epidemiological analysis of chronic rhinitis in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056609" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Natural course and comorbidities of allergic and nonallergic rhinitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16677237" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17578499" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12866316" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Rhinitis: a dose of epidemiological reality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3870504" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Non allergic rhinitis: demography of eosinophils in nasal smear, blood total eosinophil counts and IgE levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21737036" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Nonallergic rhinopathy (formerly known as vasomotor rhinitis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8116859" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Comparison of allergic rhinitis and vasomotor rhinitis patients on the basis of a computer questionnaire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1792637" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27826964" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Comorbidities and Phenotypes of Rhinitis in Korean Children and Adolescents: A Cross-sectional, Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31776689" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Occupational Rhinitis: Classification, Diagnosis, and Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22762553" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317733" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Diagnostic classification of persistent rhinitis and its relationship to exhaled nitric oxide and asthma: a clinical study of a consecutive series of patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805333" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Rhinitis and onset of asthma: a longitudinal population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20816191" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Children with allergic and nonallergic rhinitis have a similar risk of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24711681" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Allergic and non-allergic rhinitis: relationship with nasal polyposis, asthma and family history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11028656" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15245356" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The utility of specific immunoglobulin E measurements in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22643950" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A multiallergen and miniscreen can change primary care provider diagnosis and treatment of rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16839813" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : In vitro diagnosis of allergy: how to interpret IgE antibody results in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22050279" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Practical guide to skin prick tests in allergy to aeroallergens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22214511" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The benefits of specific immunoglobulin E testing in the primary care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203244" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16784007" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Rhinitis medicamentosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17044805" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725047" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Rhinitis medicamentosa: a review of causes and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19096862" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Rhinitis medicamentosa: what an otolaryngologist needs to know.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9179430" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065350" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20801120" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Proton pump inhibitor therapy improves symptoms in postnasal drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7734973" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Nonallergic rhinitis. Pathophysiology and models for study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057047" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Eosinophilic nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11897986" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9917047" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effect of steroids on nasal inflammatory cells and cytokine profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/782136" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Intra-nasal beclomethasone dipropionate in vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1526057" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : A double blind comparison of intranasal budesonide 400 micrograms and 800 micrograms in perennial rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7108069" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Effects of treatment with beclomethasone dipropionate in subpopulations of perennial rhinitis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11206234" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7584685" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6829298" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Long-term treatment with budesonide in vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10227338" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8977510" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9074948" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950898" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20674829" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7538520" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7751528" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22418065" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31677153" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Intranasal corticosteroids for non-allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19463202" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15899111" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19772756" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Intranasal antihistamines for allergic rhinitis: mechanism of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21352639" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21819751" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22143339" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Gustatory rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264159" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Efficacy and safety of oral phenylephrine: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19230461" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17636843" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Nasal saline irrigations for the symptoms of chronic rhinosinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10892694" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Clinical study and literature review of nasal irrigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1460204" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The placebo effect is nothing to sneeze at.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18025315" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Nasal saline for chronic sinonasal symptoms: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7538519" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : An overview of current pharmacotherapy in perennial rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7980900" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Endoscopic transseptal vidian neurectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1811691" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : [Anterior ethmoidal electrocoagulation in the treatment of vasomotor rhinitis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1780627" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : CO2 laser anterior turbinectomy in the treatment of non-allergic vasomotor rhinopathia. A prospective study upon 78 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7930892" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Bilateral transnasal vidian neurectomy in the management of chronic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37090861" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The effect of single kinetic oscillation stimulation treatment on nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9204653" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Vasomotor rhinitis and sphenopalatine ganglion block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26145748" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : [The modern approach to the treatment of the patients presenting with vasomotor rhinitis with the use of the electrosurgical technique].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34382444" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9249272" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1859650" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Beneficial effects of intranasal applications of capsaicin in patients with vasomotor rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27485456" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Capsaicin for Rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21802026" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21802026" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26171907" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Capsaicin for non-allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19361848" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
